Omnicell (NASDAQ:OMCL) Upgraded at StockNews.com

Omnicell (NASDAQ:OMCL - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Tuesday.

A number of other equities research analysts also recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Wells Fargo & Company lowered their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Finally, Benchmark restated a "buy" rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $50.67.

Omnicell Trading Down 2.2 %

OMCL traded down $0.67 during trading on Tuesday, hitting $30.28. The company's stock had a trading volume of 727,408 shares, compared to its average volume of 533,669. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.75. The stock has a market cap of $1.42 billion, a PE ratio of 112.15, a PEG ratio of 7.53 and a beta of 0.78. The firm's 50 day moving average price is $35.27 and its 200-day moving average price is $41.27. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, analysts expect that Omnicell will post 1.09 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in Omnicell by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock worth $48,176,000 after acquiring an additional 2,877 shares during the period. Franklin Resources Inc. boosted its stake in shares of Omnicell by 49.9% in the third quarter. Franklin Resources Inc. now owns 30,807 shares of the company's stock valued at $1,316,000 after purchasing an additional 10,260 shares during the period. Nordea Investment Management AB grew its holdings in Omnicell by 4.3% during the 4th quarter. Nordea Investment Management AB now owns 121,722 shares of the company's stock valued at $5,372,000 after purchasing an additional 5,068 shares in the last quarter. Accurate Wealth Management LLC increased its stake in Omnicell by 33.4% during the 4th quarter. Accurate Wealth Management LLC now owns 28,369 shares of the company's stock worth $1,199,000 after buying an additional 7,109 shares during the period. Finally, Arkadios Wealth Advisors lifted its holdings in Omnicell by 27.6% in the 4th quarter. Arkadios Wealth Advisors now owns 43,454 shares of the company's stock worth $1,935,000 after buying an additional 9,404 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.